薄层液基细胞学检测、人乳头瘤病毒联合鳞状细胞癌抗原在宫颈癌及癌前病变中的诊断价值

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the diagnostic value of thinprep cytologic test (TCT), human papillomavirus (HPV)combined with squamous cell carcinoma antigen (SCCA) in cervical cancer and precancerous lesions. Methods A total of 65 patients with cervical cancer and 155 patients with cervical intraepithelial neoplasia grade Ⅲwho were admitted to Jiangmen Maternity and Child Health Hospital from November 2019 to November 2020 were retrospectively selected as the cervical cancer group and precancerous lesions group, respectively. Both groups were tested for TCT and HPVDNA, and fasting venous blood was drawn to determine their serum SCCA levels by chemiluminescence method. The detection rates of TCT, HPV-DNA, serum SCCA three tests and combined tests in the two groups were compared, the sensitivity, specificity and accuracy of the three test methods alone and in combination in the diagnosis of cervical cancer were analyzed and compared. Results The detection rate of TCT, HPV-DNA, and serum SCCA in combination in the cervical cancer group was higher than that of individual examination and pairwise combined examinations, and the difference was statistically significant (P＜0.05). There was no significant difference in the detection rate of three kinds of TCT, HPV-DNA and serum SCCA examination, alone and pairwise combined examination in the precancerous lesion group (P＞0.05). The sensitivity, specificity and accuracy of TCT, HPV-DNA and serum SCCA were 100.00%,77.42% and 84.09% respectively, and the sensitivity and accuracy of diagnosis were higher than those of single examination and pairwise combined examination. Conclusion The combined application of TCT, HPV and SCCA examination can improve the detection rate of cervical cancer and improve the accuracy of diagnosis of cervical cancer and precancerous lesions, which is worthy of clinical application.

Key words： Thinprep cytologic test Human papillomavirus Squamous cell carcinoma antigen Cervical cancer Precancerous lesions

Received: 12 April 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I19/46

[1]	李兴娟，段仙芝.宫颈癌及其癌前病变筛查方案的临床价值[J].内蒙古医学杂志，2019，51（12）：1434-1436.
[2]	刘媛媛，郭瑞霞，李碧军，等.绝经后妇女子宫颈癌前病变的特点分析[J].中华妇产科杂志，2021，56（2）：114-120.
[3]	丰颖，唐丽娟，曾良，等.HR-HPV、TCT 联合电子阴道镜下宫颈活检在宫颈癌前病变及宫颈癌诊断中的应用[J].实用临床医学，2015，16（1）：61-63，76.
[4]	顾惠芳.TCT 联合HPV 用于癌前期病变和早期宫颈癌的筛查价值评价[J].系统医学，2019，4（17）：23-25.
[5]	陈多多.HR-HPV DNA 检测联合液基细胞学检查在宫颈癌及癌前病变中的筛查价值[J].医学临床研究，2019，36（4）：722-724.
[6]	郑建军.宫颈癌根治术后高危型人乳头瘤病毒、鳞状细胞癌抗原及鳞状细胞癌相关抗原检测对宫颈癌复发的预测价值[J].实用临床医药杂志，2019，23（23）：58-60.
[7]	朱晓华，张晓兰，卢锦，等.高危型人乳头状瘤病毒配合液基薄层细胞学检查在宫颈癌早期癌前病变筛查中的应用价值分析[J].中国卫生检验杂志，2019，29（12）：1502-1505.
[8]	Kostova P，Zlatkov V.The Bethesda system：new revision of the terminology from 2001 year[J].Akush Ginekol（Sofiia），2004，43（4）：52-55.
[9]	苏玥辉，张梦真，张春燕，等.FH 联合TCT、高危型HPV检测筛查宫颈癌及癌前期病变价值[J].中国计划生育学杂志，2020，28（4）：562-565.
[10]	原新丽，吴祁生，张火兵，等.液基细胞学检查在不同年龄段女性子宫颈癌前病变筛查中的现状研究[J].标记免疫分析与临床，2020，27（1）：27-31.
[11]	唐移忠，张书忠，余险峰，等.TCT 和HPV 联合检测在宫颈癌和癌前病变临床筛查的应用价值[J].解放军预防医学杂志，2019，37（5）：143-144，147.
[12]	郜静.TCT 联合HPV 检测在宫颈癌前病变筛查中的应用价值[J].河南医学研究，2020，29（2）：257-258.
[13]	李丽娟，张秋菊，樊素珍.TCT 联合HR-HPV 检测在宫颈癌及癌前病变早期筛查中的应用价值[J].癌症进展，2019，17（21）：2569-2571，2601.
[14]	陈瑶.肿瘤标志物联合TCT 与HPV DNA 检测在宫颈癌及癌前病变中的临床意义[J].健康必读，2020，15（4）：121-122.
[15]	张达衡，侯舒倩，陈红玲.液基薄层细胞学检查联合高危型人乳头瘤病毒核酸检测在宫颈癌及癌前病变筛查中的价值[J].中国医学创新，2020，17（7）：147-150.
[16]	樊长萍.福州地区健康体检女性HPV-DNA 检测联合宫颈液基细胞学检查对宫颈病变筛查的结果分析[J].中国现代医生，2020，58（25）：133-138.
[17]	吕祥瑞，方卓宁.TCT 联合HPV DNA 及血清CA15-3、SCCA、CA125 水平检测对宫颈上皮内瘤变的诊断价值[J].河南医学研究，2019，28（17）：3216-3217.